Acute myeloid leukemia: therapeutic targeting of stem cells

References

• SEER Program (National Cancer Institute (U.S.)) and National Cancer Institute (U.S.). SEER, surveillance, epidemiology, and end results program. In: NIH publication. Bethesda; 2000. p. 8.
   Google Scholar
• Gorello P. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia. 2006;20(6):1103–1108.
   PubMed Web of Science ®Google Scholar
• Chou WC. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia. 2007;21(5):998–1004.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood; 2009. 114(11): 2220–2231.
   PubMed Web of Science ®Google Scholar
• Kronke J. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol. 2011;29(19):2709–2716.
   PubMed Web of Science ®Google Scholar
• Lambert J. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. Oncotarget. 2014;5(15):6280–6288.
   PubMedGoogle Scholar
• Dick JE. Human stem cell assays in immune-deficient mice. Curr Opin Hematol. 1996;3(6):405–409.
   PubMedGoogle Scholar
• Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004;5(7):738–743.
   PubMed Web of Science ®Google Scholar
• Metcalf D, Moore MA. Factors modifying stem cell proliferation of myelomonocytic leukemic cells in vitro and in vivo. J Natl Cancer Inst. 1970;44(4):801–808.
   PubMedGoogle Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730–737.
   PubMed Web of Science ®Google Scholar
• Biorender. Adapted from “Hallmarks of Cancer: Circle.” 2021; [cited 18 Dec 2021]. Available from: https://app.biorender.com/biorender-templates
   Google Scholar
• Pollyea DA, Jordan CT, Therapeutic targeting of acute myeloid leukemia stem cells. Blood, 2017. 129(12): 1627–1635.
   PubMed Web of Science ®Google Scholar
• van Rhenen A. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005;11(18):6520–6527.
   PubMed Web of Science ®Google Scholar
• Saito Y. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med. 2010;2(17):17ra9.
   PubMed Web of Science ®Google Scholar
• Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene. 2011;30(9):1009–1019.
   PubMed Web of Science ®Google Scholar
• Goldenson BH, Goodman AM, Ball ED. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults. Expert Opin Biol Ther. 2021;21(7):849–862.
   PubMed Web of Science ®Google Scholar
• Borthakur G, Kantarjian H. Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer J. 2021;11(6):114.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM. Acute myeloid leukemia: treatment and research outlook for 2021 and the MD Anderson approach. Cancer. 2021;127(8):1186–1207.
   PubMed Web of Science ®Google Scholar
• Jordan CT. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777–1784.
   PubMed Web of Science ®Google Scholar
• Montesinos P. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia. 2021;35(1):62–74.
   PubMed Web of Science ®Google Scholar
• Sugita M, Guzman ML. CD123 as a therapeutic target against malignant stem cells. Hematol Oncol Clin North Am. 2020;34(3):553–564.
   PubMed Web of Science ®Google Scholar
• Testa U, Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood, 2002. 100(8):2980–2988.
   PubMed Web of Science ®Google Scholar
• Thomas D, Majeti R, Biology and relevance of human acute myeloid leukemia stem cells. Blood, 2017. 129(12): 1577–1585.
   PubMed Web of Science ®Google Scholar
• Tavor S. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res. 2004;64(8):2817–2824.
   PubMed Web of Science ®Google Scholar
• Lo Celso C. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature. 2009;457(7225):92–96.
   PubMed Web of Science ®Google Scholar
• Xie Y. Detection of functional haematopoietic stem cell niche using real-time imaging. Nature. 2009;457(7225):97–101.
   PubMed Web of Science ®Google Scholar
• Avecilla ST. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med. 2004;10(1):64–71.
   PubMed Web of Science ®Google Scholar
• Arima Y, Nobusue H, Saya H. Targeting of cancer stem cells by differentiation therapy. Cancer Sci. 2020;111(8):2689–2695.
   PubMedGoogle Scholar
• Wiseman DH, Greystoke BF, Somervaille TC. The variety of leukemic stem cells in myeloid malignancy. Oncogene. 2014;33(24):3091–3098.
   PubMedGoogle Scholar
• Daga S. Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling. Am J Hematol. 2020;95(10):1148–1157.
   Google Scholar
• Zhang H. Anti-CLL1 chimeric antigen receptor t-cell therapy in children with relapsed/refractory acute myeloid leukemia. Clin Cancer Res. 2021;27(13):3549–3555.
   PubMedGoogle Scholar
• Yokota A. Expression of exon v6-containing CD44 isoforms is related to poor prognosis of acute myelocytic leukemia. Hematol Oncol. 1998;16(4):131–141.
   PubMedGoogle Scholar
• Jin L. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006;12(10):1167–1174.
   PubMed Web of Science ®Google Scholar
• Vey N. Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. Oncotarget. 2016;7(22):32532–32542.
   PubMedGoogle Scholar
• Yu X. CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues. Blood, 2021. 138(12): 1067–1080.
   PubMedGoogle Scholar
• Fuchs D. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun. 2009;390(3):743–749.
   PubMedGoogle Scholar
• Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276(1):97–111.
   PubMed Web of Science ®Google Scholar
• Sinha C, Cunningham LC, Liu PP. Core binding factor acute myeloid leukemia: new prognostic categories and therapeutic opportunities. Semin Hematol. 2015;52(3):215–222.
   PubMed Web of Science ®Google Scholar
• Mardiros A. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood, 2013; 122(18):3138–3148.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol. 2006;132(4):398–409.
   PubMedGoogle Scholar
• El Khawanky N. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat Commun. 2021;12(1):6436.
   PubMedGoogle Scholar
• Brauchle B. Characterization of a novel FLT3 bite molecule for the treatment of acute myeloid leukemia. Mol Cancer Ther. 2020;19(9):1875–1888.
   PubMed Web of Science ®Google Scholar
• Arruda LCM. A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo. Haematologica. 2022. DOI:https://doi.org/10.3324/haematol.2021.279486.
   Google Scholar
• Krupka C, CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood, 2014;123(3):356–365.
   PubMed Web of Science ®Google Scholar
• Laszlo GS. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood, 2014;123(4):554–561.
   PubMed Web of Science ®Google Scholar
• Assi R. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol. 2018;25(2):136–145.
   PubMed Web of Science ®Google Scholar
• Uy GL. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood, 2021. 137( 6): p. 751–762.
   Google Scholar
• Roversi FM. Hematopoietic cell kinase (HCK) is a player of the crosstalk between hematopoietic cells and bone marrow niche through CXCL12/CXCR4 axis. Front Cell Dev Biol. 2021;9:634044.
   PubMedGoogle Scholar
• Wen ZF. Shikonin down-regulates CXCR4 expression and inhibits CXCL12-induced migratory responses in colorectal carcinoma cell line SW480. Zhonghua Wei Chang Wai Ke Za Zhi. 2009;12(6):627–629.
   PubMedGoogle Scholar
• Bila J. Bone marrow microenvironment interplay and current clinical practice in multiple myeloma: a review of the Balkan myeloma study group. J Clin Med. 2021;10(17). DOI:https://doi.org/10.3390/jcm10173940.
   Google Scholar
• Tomlinson BK. A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. Am J Hematol. 2019;94(11):E291–E294.
   PubMedGoogle Scholar
• Yao Y. Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development. Exp Hematol Oncol. 2021;10(1):39.
   PubMedGoogle Scholar
• Uy GL. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood, 2012;119(17):3917–3924.
   PubMed Web of Science ®Google Scholar
• Borthakur G. Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol. 2020;95(11):1296–1303.
   PubMedGoogle Scholar
• Fasouli ES, Katsantoni E. JAK-STAT in early hematopoiesis and Leukemia. Front Cell Dev Biol. 2021;9:669363.
   PubMedGoogle Scholar
• Kleppe M. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015;5(3):316–331.
   PubMed Web of Science ®Google Scholar
• Tam WF. STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2. Cancer Res. 2013;73(1):373–384.
   PubMedGoogle Scholar
• Sobash PT, Guddati AK, Kota V. Long-term use of ruxolitinib in an AML patient with posttransplant steroid refractory GVHD. Case Rep Oncol Med. 2020;2020:4936846.
   PubMedGoogle Scholar
• Han H. Induction of leukemic stem cell differentiation by aryl hydrocarbon receptor agonist and synergy with gilteritinib in FLT3-ITD + acute myeloid leukemia. Leuk Lymphoma. 2020;61(8):1932–1942.
   PubMed Web of Science ®Google Scholar
• Chen Y. Oxidative resistance of leukemic stem cells and oxidative damage to hematopoietic stem cells under pro-oxidative therapy. Cell Death Dis. 2020;11(4):291.
   PubMed Web of Science ®Google Scholar
• Kuntz EM. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nat Med. 2017;23(10):1234–1240.
   PubMed Web of Science ®Google Scholar
• Chen C. Oxidative phosphorylation enhances the leukemogenic capacity and resistance to chemotherapy of B cell acute lymphoblastic leukemia. Sci Adv. 2021;7(11):1234–1240.
   Google Scholar
• Pavlides S. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 2009;8(23):3984–4001.
   PubMed Web of Science ®Google Scholar
• Uhl FM. Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans. Sci Transl Med. 2020;12(567).
   PubMed Web of Science ®Google Scholar
• Satoh T, Kaida D. Upregulation of p27 cyclin-dependent kinase inhibitor and a C-terminus truncated form of p27 contributes to G1 phase arrest. Sci Rep. 2016;6(1):27829.
   PubMedGoogle Scholar
• Arai F. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 2004;118(2):149–161.
   PubMed Web of Science ®Google Scholar
• Guzman RE. Preferential association with ClC-3 permits sorting of ClC-4 into endosomal compartments. J Biol Chem. 2017;292(46):19055–19065.
   PubMedGoogle Scholar
• Sykes DB. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell. 2016;167(1):171–186 e15.
   PubMed Web of Science ®Google Scholar
• Sykes DB. The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia. Expert Opin Ther Targets. 2018;22(11):893–898.
   PubMed Web of Science ®Google Scholar
• Maguer-Satta V, Besancon R, Bachelard-Cascales E. Concise review: neutral endopeptidase (CD10): a multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells. 2011;29(3):389–396.
   PubMed Web of Science ®Google Scholar
• Tabe Y, Konopleva M, Andreeff M. Fatty acid metabolism, bone marrow adipocytes, and AML. Front Oncol. 2020;10:155.
   PubMedGoogle Scholar
• Tcheng M. Very long chain fatty acid metabolism is required in acute myeloid leukemia. Blood, 2021. 137(25): 3518–3532.
   PubMed Web of Science ®Google Scholar
• Stevens BM. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020;1(12):1176–1187.
   PubMedGoogle Scholar
• Kumar B. Harnessing the metabolic vulnerabilities of leukemia stem cells to eradicate acute myeloid leukemia. Front Oncol. 2021;11:632789.
   PubMedGoogle Scholar
• O’Reilly E, Zeinabad HA, Szegezdi E. Hematopoietic versus leukemic stem cell quiescence: challenges and therapeutic opportunities. Blood Rev. 2021;50:100850.
   PubMedGoogle Scholar
• Quotti Tubi L. Protein kinase CK2 regulates AKT, NF-kappaB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia. Leukemia. 2017;31(2):292–300.
   PubMed Web of Science ®Google Scholar
• Bian Y. MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer. Int J Biol Sci. 2015;11(4):411–422.
   PubMed Web of Science ®Google Scholar
• Castelli G, Pelosi E, Testa U. Emerging therapies for acute myelogenus leukemia patients targeting apoptosis and mitochondrial metabolism. Cancers (Basel). 2019;11(2):260.
   Google Scholar
• Xie SZ. Sphingosine-1-phosphate receptor 3 potentiates inflammatory programs in normal and leukemia stem cells to promote differentiation. Blood Cancer Discov. 2021;2(1):32–53.
   PubMedGoogle Scholar
• Yamashita M. Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis. Nat Rev Cancer. 2020;20(7):365–382.
   PubMed Web of Science ®Google Scholar
• Hopner SS. LIGHT/LTbetaR signaling regulates self-renewal and differentiation of hematopoietic and leukemia stem cells. Nat Commun. 2021;12(1):1065.
   PubMedGoogle Scholar
• Jakubowska MA, Kerkhofs M, Martines C. ABT-199 (Venetoclax), a BH3-mimetic Bcl-2 inhibitor, does not cause Ca2+ -signalling dysregulation or toxicity in pancreatic acinar cells. Br J Pharmacol. 2019;176(22):4402–4415.
   PubMedGoogle Scholar
• Zhang Q. Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther 2022; 7( 1):51.
   PubMed Web of Science ®Google Scholar
• Lagadinou ED. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12(3):329–341.
   PubMed Web of Science ®Google Scholar
• Guerra VA, DiNardo C, Konopleva M. Venetoclax-based therapies for acute myeloid leukemia. Best Pract Res Clin Haematol. 2019;32(2):145–153.
   PubMed Web of Science ®Google Scholar
• DiNardo CD. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood, 2019; 133(1):7–17.
   PubMed Web of Science ®Google Scholar
• DiNardo CD. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
   PubMed Web of Science ®Google Scholar
• Jones CL. Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells. Cell Stem Cell. 2020;27(5):748–764 e4.
   PubMed Web of Science ®Google Scholar
• Jones CL. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018;34(5):724–740 e4.
   PubMed Web of Science ®Google Scholar
• Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009;1(4):a000034.
   PubMed Web of Science ®Google Scholar
• Yi H. Resveratrol alleviates the interleukin-1beta-induced chondrocytes injury through the NF-kappaB signaling pathway. J Orthop Surg Res. 2020;15(1):424.
   PubMedGoogle Scholar
• Liu R. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11(9):797.
   PubMed Web of Science ®Google Scholar
• Panieri E, Saso L. Potential applications of NRF2 inhibitors in cancer therapy. Oxid Med Cell Longev. 2019;2019:8592348.
   PubMedGoogle Scholar
• Lobry C. Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med. 2013;210(2):301–319.
   PubMed Web of Science ®Google Scholar
• Wang S. Expression of microRNA miR-34a inhibits leukemia stem cells and its metastasis. Eur Rev Med Pharmacol Sci. 2016;20(13):2878–2883.
   PubMedGoogle Scholar
• Zhou W. HOTAIR suppresses PTEN via DNMT3b and confers drug resistance in acute myeloid leukemia. Hematology. 2021;26(1):170–178.
   PubMed Web of Science ®Google Scholar
• Li M. HOTAIR participates in hepatic insulin resistance via regulating SIRT1. Eur Rev Med Pharmacol Sci. 2018;22(22):7883–7890.
   PubMed Web of Science ®Google Scholar
• Li Z. Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway. Exp Ther Med. 2019;18(1):435–442.
   PubMed Web of Science ®Google Scholar
• Xue X. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene. 2016;35(21):2746–2755.
   PubMed Web of Science ®Google Scholar
• Gourvest M, Brousset P, Bousquet M. Long noncoding RNAs in acute myeloid leukemia: functional characterization and clinical relevance. Cancers (Basel). 2019;11(11):1638.
   PubMed Web of Science ®Google Scholar
• Bill M. Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells. Leukemia. 2019;33(9):2169–2182.
   PubMedGoogle Scholar
• Marchand T, Pinho S. Leukemic stem cells: from leukemic niche biology to treatment opportunities. Front Immunol. 2021;12:775128.
   PubMedGoogle Scholar
• Smitheman KN. Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes. Haematologica. 2019;104(6):1156–1167.
   PubMed Web of Science ®Google Scholar
• Salamero O. First-in-human phase i study of iadademstat (ORY-1001): a first-in-class lysine-specific histone demethylase 1a inhibitor, in relapsed or refractory acute myeloid leukemia. J Clin Oncol. 2020;38(36):4260–4273.
   PubMedGoogle Scholar
• Cuyas E. The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes. Aging (Albany NY). 2020;12(6):4794–4814.
   PubMedGoogle Scholar
• Bernt KM, Armstrong SA. A role for DOT1L in MLL-rearranged leukemias. Epigenomics. 2011;3(6):667–670.
   PubMedGoogle Scholar
• Wang WT. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia. J Hematol Oncol. 2020;13(1):78.
   PubMedGoogle Scholar
• Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7(11):823–833.
   PubMed Web of Science ®Google Scholar
• Krivtsov AV. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442(7104):818–822.
   PubMed Web of Science ®Google Scholar
• Neff T, Armstrong SA, Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood, 2013; 121(24): 4847–4853.
   PubMedGoogle Scholar
• Basati G. Cancer stem cells and nanotechnological approaches for eradication. Stem Cell Investig. 2019;6:38.
   PubMedGoogle Scholar
• Raineri S, Mellor J. IDH1: linking metabolism and epigenetics. Front Genet. 2018;9:493.
   PubMedGoogle Scholar
• Jan M. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med. 2012;4(149):149ra118.
   PubMed Web of Science ®Google Scholar
• Mathew NR. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018;24(3):282–291.
   PubMed Web of Science ®Google Scholar
• Zhang Z. Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant; 2022;24(3):282–291.
   Google Scholar
• Paczulla AM. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature. 2019;572(7768):254–259.
   PubMed Web of Science ®Google Scholar
• Lapidot T. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645–648.
   PubMed Web of Science ®Google Scholar
• Biorender. 2021.
   Google Scholar